{"id":16977,"date":"2023-10-19T08:24:23","date_gmt":"2023-10-19T08:24:23","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/"},"modified":"2023-10-19T08:24:23","modified_gmt":"2023-10-19T08:24:23","slug":"sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases","status":"publish","type":"blog","link":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/","title":{"rendered":"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases"},"content":{"rendered":"

Sygnature Discovery has been selected by Insmed Innovation<\/a> UK, the Cambridge-based subsidiary of Insmed Incorporated, a global biopharmaceutical company headquartered in New Jersey, USA, to partner on an integrated drug discovery<\/a> collaboration.<\/span><\/p>\n

Insmed will draw on Sygnature Discovery\u2019s considerable expertise in bringing together scientific disciplines to deliver compounds against novel biological targets for genetically defined diseases.<\/span><\/p>\n

These novel targets are the basis for several programmes initiated by Insmed that aim to deliver first-in-class therapeutics to patient populations with severe unmet medical needs.<\/span><\/p>\n

 <\/p>\n

Stuart Onions, Senior Vice-President, Alliance Management at Sygnature Discovery, said:<\/strong><\/span><\/p>\n

\u201cSygnature and Insmed are truly complementary teams. We work seamlessly together allowing each party to focus on what they know best: compelling new areas of biology, target discovery and validation in the case of Insmed, and multi-disciplinary, multi-modality drug design and development in ours.<\/span><\/p>\n

\u00ab\u00a0The Sygnature team are truly excited by the collaboration \u2013 our second with this team.\u201d<\/span><\/p>\n

 <\/p>\n

Tom Heightman, SVP Research at Insmed, also commented:<\/strong><\/span><\/p>\n

\u201cHaving worked successfully with Sygnature in the past and knowing their team of experienced scientists, track record, and infrastructure, it was a pleasure to select Sygnature as a strategic partner.<\/span><\/p>\n

\u00ab\u00a0Sygnature\u2019s co-located scientific operations allow for rapid design-make-test cycles across all services, including protein crystallography, biophysics, and medicinal chemistry. \u00a0We look forward to making rapid progress on the novel targets we are working on together.\u201d<\/span><\/p>\n

 <\/p>\n

About Sygnature Discovery <\/strong><\/span><\/p>\n

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation based in the UK and Canada with its headquarters in Nottingham and additional sites in Alderley Park, Macclesfield, Glasgow, Montreal and Quebec City. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations. Since 2004, Sygnature Discovery has delivered over 40 novel pre-clinical and 22 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.<\/p>\n","protected":false},"featured_media":13655,"template":"","category":[29],"class_list":["post-16977","blog","type-blog","status-publish","has-post-thumbnail","hentry","category-non-categorise"],"acf":[],"yoast_head":"\nSygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases - Sygnature\" \/>\n<meta property=\"og:description\" content=\"Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/\",\"name\":\"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Discovery-Bldg-4-Apr-2017-web-cropped.jpg\",\"datePublished\":\"2023-10-19T08:24:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Discovery-Bldg-4-Apr-2017-web-cropped.jpg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Discovery-Bldg-4-Apr-2017-web-cropped.jpg\",\"width\":1000,\"height\":587},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/","og_locale":"fr_CA","og_type":"article","og_title":"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases - Sygnature","og_description":"Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/","og_site_name":"Sygnature","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/","name":"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Discovery-Bldg-4-Apr-2017-web-cropped.jpg","datePublished":"2023-10-19T08:24:23+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Discovery-Bldg-4-Apr-2017-web-cropped.jpg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Discovery-Bldg-4-Apr-2017-web-cropped.jpg","width":1000,"height":587},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/sygnature-discovery-partners-with-insmed-to-develop-first-in-class-compounds-for-genetically-defined-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog\/16977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/blog"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog\/16977\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/13655"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=16977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=16977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}